More on Vivus (VVUS): Q4 misses across the board as loss widened as operating expenses soared to $58.3M in the latest period. In contrast, the company recognized just $2M in product revenue from Qsymia sales. Analysts on average expected sales of around $3M. Shares -2.8% AH.
More on Vivus (VVUS): Q4 misses across the board as loss widened as operating expenses soared to...
From other sites
at CNBC.com (Dec 2, 2014)
at CNBC.com (Dec 1, 2014)
at CNBC.com (Oct 27, 2014)
at CNBC.com (Sep 18, 2014)
at CNBC.com (Sep 11, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs